Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | PNMT | P11086 | 2/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.43 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | AGXT | P21549 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21902246 | 0.84 | TSHR (0.51) | TSHRRECQLTAAR1PNMTAOC3 | |
| SCHEMBL31500392 | 0.82 | TSHR (0.53) | TSHRRECQLTAAR1PNMTAOC3 | |
| SCHEMBL11466186 | 0.82 | TSHR (0.53) | TSHRRECQLTAAR1PNMTAOC3 | |
| SCHEMBL21902245 | 0.81 | TSHR (0.49) | TSHRRECQLTAAR1PNMTAOC3 | |
| SCHEMBL21902239 | 0.81 | TSHR (0.51) | TSHRRECQLTAAR1PNMTAOC3 | |
| SCHEMBL14614770 | 0.79 | PYCR1 (0.56) | TSHRRECQLTAAR1PNMTAOC3 | |
| SCHEMBL26655849 | 0.77 | TAAR1 (0.46) | TSHRRECQLTAAR1PNMTAOC3 | |
| SCHEMBL26658419 | 0.75 | TAAR1 (0.47) | TSHRRECQLTAAR1PNMTAOC3 | |
| SCHEMBL21902241 | 0.75 | CARM1 (0.62) | TSHRRECQLTAAR1PNMTAOC3 | |
| SCHEMBL26655852 | 0.74 | TAAR1 (0.46) | TSHRRECQLTAAR1PNMTAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023203254-A2 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2023-10-26 | — | — | WO | disclosed |